Heart Transplantation Articles & Analysis: Older
34 news found
In 2024, we are focusing our efforts on two of our most promising programs: Hypoplastic Left Heart Syndrome (HLHS); and Alzheimer's Disease. HLHS: HLHS is a rare pediatric disease affecting approximately 1000 live births per year in the US. The results of our successful Phase 1 trial showed 100% transplant free survival of all subjects at up to 5 years of age. ...
Puzzle Medical Devices Inc. is delighted to announce its first-in-human results for the ModulHeart have been presented at the prestigious American Heart Association (AHA) meeting held November 5–7, 2022 at the McCormick Place Convention Center in Chicago, IL. Montreal-based Puzzle Medical Devices Inc. (PMD) developed a percutaneous heart pump designed to ...
The results were presented during a moderated poster session at the Heart Failure Society of America’s Annual Scientific Meeting on September 30, 2022. ...
Montreal-based Puzzle Medical Devices Inc. (PMD) developed a percutaneous heart pump designed to support cardiac and renal function in patients with advanced heart failure (HF). ...
rst-in-human study to evaluate the performance of its ModulHeart percutaneous heart pump designed to reduce cardiac afterload and improve renal perfusion in patients with advanced heart failure (HF). ...
– July 12, 2022 – Ancora Heart, Inc., a company developing a novel device-based therapy to address heart failure, today announced that the U.S. ...
Procyrion, Inc., a medical device company developing a catheter-deployed micropump for the management of chronic heart failure, has named Eric S. Fain, MD as President and Chief Executive Officer effective immediately. ...
Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, announces new data validating the benefits of the Company’s BVA-100 blood test (BVA) in improving survival for advanced heart failure patients with left ventricular assist device (LVAD). These data were presented at the International Society for Heart and Lung ...
BKV is detected in up to 20% of kidney transplant patients and can lead to graft loss and a return to end-stage renal disease and dialysis. ...
ByKalaris
Following the 2021 update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment and the recently presented GUIDE-HF data, the FDA’s decision underscores the clinical benefits of PA pressure-guided HF management for New York Heart Association (NYHA) class III heart failure patients2,3. ...
CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure, announces the completion of investigations on its prostheses. Following the occurrence of a quality issue ...
ByCarmat
CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to fulfill an unmet medical need by providing a therapeutic alternative to people suffering from end-stage biventricular heart failure,announces the first implant of theAeson artificial heart in The Netherlands. ...
ByCarmat
CARMAT (FR0010907956, ALCAR), the designer and developer of the world’s most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from end-stage biventricular heart failure, today announces the third implant of its Aeson® bioprosthetic artificial heart in a commercial setting. ...
ByCarmat
The company’s first product, the SherpaPak Cardiac Transport System (CTS), is designed to protect heart transplants from physical and thermal trauma in a dual-canister compartment. ...
CorWave, a French medical device company committed to the fight against heart failure, unveiled an unprecedented study on the performance of its implantable heart pump at the 41st Annual Meeting of the International Society for Heart and Lung Transplantation (ISHLT). ...
ByCorWave
Thomas Schöndorf, Manager Clinical Research at Berlin Heart. “All these children suffer from advanced heart failure and are waiting for a heart transplantation. ...
To overcome this, they urgently need a donor heart. While these significant comorbidities indicate a heart transplantation, at the same time, they worsen its chance of success. ...
Estep specializes in managing advanced heart failure patients and is the Head of the Section of Heart Failure and Transplantation in the Tomsich Family Department of Cardiovascular Medicine in the Sydell and Arnold Miller Family Heart, Vascular and Thoracic Institute at the prestigious Cleveland Clinic. He has participated in ...
Commercial opportunity and plan Significant market opportunity The CE marking for the CARMAT heart as a bridge-to-transplant (BTT) represents a very significant market opportunity with a minimum of 2,000 patients currently on waiting lists for a heart transplant in five major European countries[5]. ...
ByCarmat
For the very first time, AdjuCor GmbH's revolutionary new heart-assist technology – BEAT – will take the stage at the prestigious 41st International Society for Heart and Lung Transplantation (#ISHLT2021). ...